Tag: Cancer: Cervical
Decline Observed in HPV Type 16/18 Cervical Precancers in U.S.
Greatest declines seen among vaccinated women; decreases also seen in unvaccinated women
44.4 Million Estimated to Be Diagnosed With Cervical Cancer by 2069
From 2020 to 2069, 6.7 to 7.7 million cases could be averted by scaling up HPV vaccination by 2020
Algorithm Evaluates Cervical Images to ID Precancer, Cancer
Deep learning-based algorithm was validated using archived, digitized cervical screening images
Cervical Cancer Screening Rates ‘Unacceptably Low’
Just 64.6 percent of 30- to 65-year-old women up to date, but Pap-HPV cotesting has increased
HPV Ups Cervical Cancer Risk, Even With No Cellular Signs
HPV-16/18 confers strong future risk, particularly in women younger than 30 years
Age to Stop Cervical Cancer Screening Depends on Test Used
Negative HPV test, HPV-cytology co-test tied to low remaining lifetime cancer risk for unvaccinated
Minimally Invasive Sx May Up Mortality in Early Cervical Cancer
Two studies show increased mortality and reduced disease-free, overall survival versus open surgery
Positive HPV Status Tied to Better Cervical Cancer Prognosis
Five-year relative survival ratio better for hrHPV-positive cases than for hrHPV-negative cases
Catch-Up HPV Doses Effective to Age 21 Against Cervical Neoplasia
But catch-up doses not effective against CIN for women who initiated vaccination at 21 to 26 years
USPSTF Updates Guidance for Cervical Cancer Screening
Cytology recommended every three years from age 21; different screening options from age 30 to 65
